NEW YORK (GenomeWeb) – NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.

As a designated sequencing lab for the trial, the Fort Myers, Florida-based company will use its NeoType Discovery Panel to identify patients who may be eligible for treatment of their tumor types at clinical sites participating in NCI-MATCH. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.